StreetInsider.com News Articles

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Wed, 09 Sep 2026 16:15:00 -0400

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Wed, 09 Sep 2026 16:15:00 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) has entered into definitive agreements for the immediate exercise of certain outstanding warrants, expected to generate approximately $5.9 million in gross proceeds before placement agent fees and other expenses.

The transaction involves the exercise of warrants to purchase an aggregate of 453,969 shares of common stock at a reduced exercise price of $12.92 per share. The warrants were originally issued on four separate dates between February 2024 and December 2025, with original exercise prices ranging from $17.85 to $45.90 per share. The transaction is expected to close on or about September 9, 2026, subject to

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Bioscience raises $5.9M through warrant exercise

Tue, 08 Sep 2026 08:02:32 -0400

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Tue, 08 Sep 2026 08:00:00 -0400

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Fri, 04 Sep 2026 09:20:00 -0400

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14^th through September 16^th, 2026 in New York City.

Richard Christopher, CEO of Lexaria Bioscience Corp, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The presentation will be available to view online using this link.

Event Details:

Conference: 28th Annual H.C. Wainwright Global

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Fri, 04 Sep 2026 09:20:00 -0400

Event Details:

Conference: 28th Annual H.C. Wainwright Global

Lexaria receives $2.6M tax rebate from Australian R&D program

Tue, 01 Sep 2026 09:15:40 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) has received a cash rebate of AUD$3,666,611.98 (approximately USD$2.6 million) from the Australian Tax Office, according to a statement from the company.

The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary, Lexaria (AU) Pty Ltd. The rebate was granted under Australia's Research & Development Tax Incentive Program following a review of the company's 2025 application, which verified compliance with the program's requirements.

The rebate is connected to Lexaria's 12-week chronic GLP-1-H24-4 Study, which the company conducted in Australia. Lexaria said it intends to use the proceeds for future R&D activities in Australia.

"This is

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Tue, 01 Sep 2026 09:15:00 -0400

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate

KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.

Lexaria strategically performed its previous 12-week chronic GLP-1-H24-4 Study in Australia, fully aware of certain potential tax advantages in

Lexaria Receives USD$2.6 Million Tax Rebate Payment

Tue, 01 Sep 2026 09:15:00 -0400

Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate

Lexaria strategically performed its previous 12-week chronic GLP-1-H24-4 Study in Australia, fully aware of certain potential tax advantages in

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Mon, 24 Aug 2026 09:10:00 -0400

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study
Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated
Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs

KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK")

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Mon, 24 Aug 2026 09:10:00 -0400

Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study
Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated
Findings support Lexaria's expanding strategic partnering outreach activities by evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs

Form 8-K Lexaria Bioscience Corp. For: Aug 17

Mon, 17 Aug 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260817/26937000.html

Form 8-K Lexaria Bioscience Corp. For: Aug 17

Mon, 17 Aug 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260817/26937000.html

Lexaria signs material transfer agreement with PegBio for GLP-1 study

Thu, 13 Aug 2026 09:02:16 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) has entered into a Material Transfer Agreement (MTA) with PegBio Co., Ltd (HKG: 2565) to evaluate Lexaria's DehydraTECH drug delivery technology with a proprietary GLP-1 molecule being developed by PegBio.

Under the agreement, PegBio will supply Lexaria with a proprietary GLP-1 molecule, which Lexaria will then process using its patented DehydraTECH technology and evaluate for pharmacokinetic performance in animal studies. Lexaria said the MTA is separate from a pre-existing material transfer agreement it holds with another, unnamed pharmaceutical company.

PegBio is a biotechnology company focused on metabolic and related chronic diseases. Its first internally developed drug, PB-119

Lexaria Enters a Material Transfer Agreement With PegBio

Thu, 13 Aug 2026 09:00:00 -0400

KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.

The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1

Lexaria Enters a Material Transfer Agreement With PegBio

Thu, 13 Aug 2026 09:00:00 -0400

The MTA details the conditions under which PegBio will supply Lexaria with a proprietary GLP-1

Form 8-K Lexaria Bioscience Corp. For: Aug 04

Mon, 10 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26898965.html

Form 8-K Lexaria Bioscience Corp. For: Aug 04

Mon, 10 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26898965.html

Form 8-K Lexaria Bioscience Corp. For: Jul 29

Thu, 30 Jul 2026 12:03:00 -0400

si-local-file:///var/storage/secattach/20260730/26841690.html